Expression and prognostic relevance of STAT3 and cyclin D1 in non-small cell lung cancer
- 1 April 2012
- journal article
- research article
- Published by SAGE Publications in The International Journal of Biological Markers
- Vol. 27 (2), 132-138
- https://doi.org/10.5301/jbm.2012.9146
Abstract
To guide clinicians in selecting treatment options for patients with non-small cell lung cancer (NSCLC), it is desirable to have reliable markers predicting clinical outcome. This study analyzed the correlation between signal transducer and activator of transcription 3 (STAT3) and cyclin D1 in NSCLC and their association with clinicopathological features and survival. We investigated 65 specimens of NSCLC tissues by immunohistochemistry using STAT3 and cyclin D1 antibodies. First we determined the correlation between STAT3 and cyclin D1 expression and the clinicopathological features of the tumor. Then we assessed the prognostic relevance of STAT3 and cyclin D1. A significant correlation was found between high levels of STAT3 expression and the degree of tumor differentiation. Additionally, a significant positive correlation was found between the expression of STAT3 and cyclin D1 (r=0.405, p=0.001). The overexpression of STAT3 and the presence of metastasis were significantly associated with shorter overall survival in univariate analysis (p=0.028 and p=0.036, respectively). Multivariate analysis confirmed that STAT3 expression was an independent prognostic factor (p=0.001). STAT3 might be correlated with tumor differentiation, and its elevated expression may be an adverse prognostic indicator for patients with NSCLC. Activation of the STAT3/cyclin D1 signaling pathway may be attributed to the malignant transformation of NSCLC and may represent a possible target for therapy.Keywords
This publication has 21 references indexed in Scilit:
- Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Ras-induced transformationBreast Cancer Research, 2010
- Deregulation of p27 and Cyclin D1/D3 Control Over Mitosis Is Associated with Unfavorable Prognosis in Non-small Cell Lung Cancer, as Determined in 405 Operated PatientsJournal of Thoracic Oncology, 2010
- Updates in non-small cell lung cancer - insights from the 2009 45th annual meeting of the American Society of Clinical OncologyJournal of Hematology & Oncology, 2010
- Loss of Bcl-2 expression in colon cancer: A prognostic factor for recurrence in stage II colon cancerSurgical Oncology, 2009
- Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patientsBritish Journal of Cancer, 2008
- STAT3 as a central mediator of neoplastic cellular transformationCancer Letters, 2007
- Cell cycle related proteins as prognostic parameters in radically resected non-small cell lung cancerJournal of Clinical Pathology, 2005
- Prognostic value of cyclin D1 overexpression in correlation with pRb and p53 status in non-small cell lung cancer (NSCLC)Zeitschrift für Krebsforschung und Klinische Onkologie, 2005
- Evaluation of immunohistochemical markers in non‐small cell lung cancer by unsupervised hierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markersThe Journal of Pathology, 2004
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004